Type-2 Diabetes Drug Curbs Heart Failure Risk in Patients

A Type-2 diabetes drug has the potential to prevent hospitalizations due to heart failure in diabetic patients who never had the condition before.

Results of a clinical trial shows that a Type-2 diabetes drug significantly reduces hospitalizations and death from heart failure.

The researchers also found that the drug has the potential to prevent heart failure in diabetic patients who never had the condition before.

Men, Women may Need Gender-Specific Heart Failure Treatment
Johns Hopkins scientists shed light on different forms of heart failure seen in men and women that may require the development of gender-specific treatments.

‘A Type-2 diabetes drug not only appeared to prevent deterioration in patients who already had heart failure, but also appeared to prevent that condition from developing in patients who never had it before in life.’

"One conclusion that could be proposed is that the drug not only appeared to prevent deterioration in patients who already had heart failure but also appeared to prevent that condition from developing in patients who never had it before," said one of the researchers Silvio Inzucchi, professor at Yale School of Medicine in New Haven in the US.

Many individuals with Type-2 diabetes also have heart failure, a condition in which the heart fails to pump blood effectively.

Treatment for heart failure is limited and prior efforts to treat patients with Type-2 diabetes drugs showed no benefit for heart failure.

Higher Level of Physical Activity Lowers the Risk of Developing Heart Failure
Walking 30 minutes a day might not be enough for healthy heart, so one should do more physical activity to reduce the risk of heart failure.

But a new class of Type-2 diabetes drugs (SGLT2 inhibitors) that reduce blood sugar by increasing its excretion in the urine had not been studied.

In the new trial, patients with Type-2 diabetes and risk factors for heart disease were randomized to receive once-daily doses of either the glucose-lowering drug empagliflozin (10 mg or 25 mg doses), or a placebo.

Novartis Waiting for Regulators Approval to Market Its New Heart Failure Drug in Europe
Once European Commission approves Entresto, it will be available for the treatment of adult patients with symptomatic chronic reduced ejection fraction (HFrEF).

The drug or placebo was given in addition to standard care. At the end of the trial period, investigators found that patients treated with the drug experienced reductions in blood sugar and blood pressure, as well as weight loss, compared to those on placebo.

They also found major significant reductions in hospitalizations for heart failure (35 percent). The findings were presented at the 2015 American Heart Association (AHA) scientific session in Orlando, Florida.

23-Year-Old With End Stage Heart Failure Gets a New Lease of Life After a Heart Transplant
Doctors had no other go than heart transplant to save Oshin Goyal suffering from restrictive cardio-myopathy, where a timely green corridor saved her life.

Source-IANS